By Fineline Cube Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company, has announced the start of a Phase III clinical study in the Chinese mainland for its HER2-targeted antibody drug conjugate (ADC), FS-1502. The study is focused on the treatment of HER2-positive unresectable, locally advanced, or metastatic breast cancer.
FS-1502 Development and Licensing Background
FS-1502 was acquired by Fosun Pharma for development in Greater China under a licensing agreement with South Korea-based LegoChem Biosciences Inc., signed in August 2015. This strategic partnership has positioned Fosun Pharma to contribute to the growing field of targeted cancer therapies in the region. The drug is also under investigation in a Phase II clinical study for non-small cell lung cancer and in combination with HanSiZhuang (serplulimab) and/or chemotherapy for HER2-expressing advanced gastric cancer.
Market Landscape for HER2-Targeted ADCs in China
The Chinese market currently features three HER2-targeted ADCs, including Roche’s Kadcyla (trastuzumab emtansine), AstraZeneca/Daiichi Sankyo’s fam-trastuzumab deruxtecan, and RemeGen’s disitamab vedotin. The entry of FS-1502 into late-stage clinical trials signifies Fosun Pharma’s commitment to expanding treatment options for patients with HER2-positive cancers and potentially enhancing the competitive landscape of targeted therapies in China.-Fineline Info & Tech